Assessment of the Admission and Follow-up Characteristics of Children Diagnosed with Secondary Osteoporosis
PDF

Original Article

Assessment of the Admission and Follow-up Characteristics of Children Diagnosed with Secondary Osteoporosis

J Clin Res Pediatr Endocrinol 2024;16(4):466-474 DOI: 10.4274/jcrpe.galenos.2024.2024-4-4
, , , , , ,
PDF
Permissions

Abstract

Objective

Secondary osteoporosis is a condition when the underlying disease or its treatment causes the bone mass to decrease and the bone structure to deteriorate, increasing the risk of fracture. The importance of diagnosis and treatment during childhood and adolescence is due to the long-term negative effects. In this study, our objectives were to determine the diagnostic findings, treatment efficacy, and follow-up characteristics of children with secondary osteoporosis.

Methods

Patients diagnosed with secondary osteoporosis between January 2000 and January 2021 were included. The research was a cross-sectional and descriptive study. Study participants had to be under 18 years of age when the primary underlying disease was diagnosed and had received treatment for secondary osteoporosis. Patient data were collected from patient files. Statistical analysis was performed using Statistical Package for the Social Sciences, version 20.0 (IBM Corp, Armonk, NY, USA).

Results

Sixty-one patients (28 female; 45.9%) were evaluated. The most common underlying primary diseases were inflammatory diseases (57.7%), neuromuscular diseases (26.2%), immunodeficiency (13.1%), acute lymphoblastic leukemia (8.2%), metabolic diseases (8.2%), solid organ transplantation (8.2%), bone marrow transplantation (6.6%) and epilepsy (6.6%). The mean±standard deviation chronological age when secondary osteoporosis was diagnosed was 11.89±4.88 years. Patients were evaluated for osteoporosis at a mean of 6.39±5.13 years after the onset of the underlying primary chronic diseases. Most (78.7%) had a history of one or more chronic drug use, including systemic steroids (59%), chemotherapeutics (23%), immunomodulatory drugs (19.7%), antiepileptic drugs (8.2%), inhaled steroids (4.9%), intravenous immunoglobulin (1.6%), and antituberculosis drugs 1.6%.Bone pain was detected in 49.2%. All patients had vertebral fractures before treatment. Bisphosphonate treatment was given to 45 (73.8%). There was a significant increase in mean bone mineral density (BMD) and bone mineral content six months after treatment (both p<0.001). There was a significant increase in BMD Z-score values for chronological and height age (both p<0.001). Overall mean BMD values increased by 31.15% with treatment. Following bisphosphonate treatment, there was a significant reduction in both fracture number and bone pain (p<0.01). Similar benefits from bisphosphonate treatment were evident in those who did or did not receive steroid treatment.

Conclusion

Secondary osteoporosis is a condition that is influenced by many factors, such as the primary disease causing osteoporosis and chronic medication use, especially steroids. If left untreated, osteoporosis may lead to clinically important morbidity (bone pain, fractures, immobilization) and reduced linear growth of bone. When used to treat childhood secondary osteoporosis, bisphosphonates significantly improve BMD and reduced fracture risk.

Keywords: Childhood, secondary osteoporosis, bisphosphonate

Read the full text

5 sections · 1 figure · 5 tables · PDF

Create your free account to read the full text.

  • Full text with figures and tables
  • PDF and supplementary files
  • Access on every Galenos journal
Get free access

Already have an account?

Sign in
or
Continue with Google

One Galenos account works on every Galenos journal site.

References

1

Shaw NJ. Management of osteoporosis in children. Eur J Endocrinol. 2008;159(Suppl 1):S33-39. Epub 2008 Sep 4.

2

Madhuchani D, Seneviratne SN, Ward LM. Bone health in childhood and adolescence: an overview on dual-energy X-ray absorptiometry scanning, fracture surveillance and bisphosphonate therapy for low-middle-income countries. Front Endocrinol (Lausanne). 2023;14:1082413.

3

Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, Lewiecki EM, Morse LR, Rosen HN, Weber DR, Zemel BS, Shepherd JA. Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. J Clin Densitom. 2019;22:453-471. Epub 2019 Jul 5

4

Özen T, Özışık L, Başaran NÇ. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4:46-56. Epub 2016 Dec 30

5

Dittrich AT, Janssen EJ, Geelen J, Bouman K, Ward LM, Draaisma JM. Diagnosis, Follow-Up and Therapy for Secondary Osteoporosis in Vulnerable Children: A Narrative Review. Appl Sci. 2023;13:4491.

6

Jin HY, Noh ES, Hwang IT. Diagnosis and Management of Osteoporosis in Children and Adolescents. Ewha Med J. 2023;46:e18.

7

Neyzi O, Bundak R, Gökçay G, Günöz H, Furman A, Darendeliler F, Baş F. Reference Values for Weight, Height, Head Circumference, and Body Mass Index in Turkish Children. J Clin Res Pediatr Endocrinol. 2015;7:280-293.

8

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911-1930. Epub 2011 Jun 6 Erratum in: J Clin Endocrinol Metab. 2024;109:e1991.

9

Demir K, Özen S, Konakçı E, Aydın M, Darendeliler F. A Comprehensive Online Calculator for Pediatric Endocrinologists: ÇEDD Çözüm/TPEDS Metrics. J Clin Res Pediatr Endocrinol. 2017;9:182-184. Epub 2017 Apr 26

10

Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-1148.

11

Inoue Y, Mitsunaga K, Yamamoto T, Chiba K, Yamaide F, Nakano T, Morita Y, Yamaide A, Suzuki S, Arima T, Yamaguchi KI, Tomiita M, Shimojo N, Kohno Y. Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study. Pediatr Rheumatol Online J. 2018;16:36.

12

Zacharin M, Lim A, Gryllakis J, Siafarikas A, Jefferies C, Briody J, Heather N, Pitkin J, Emmanuel J, Lee KJ, Wang X, Simm PJ, Munns CF. Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy. J Clin Endocrinol Metab. 2021;106:2328-2342.

13

Lim DBN, Moon RJ, Davies JH. Advances in Diagnosis and Management of Childhood Osteoporosis. J Clin Res Pediatr Endocrinol. 2022;14:370-384. Epub 2022 Aug 19

14

Saraff V, Högler W. Endocrinology and adolescence: osteoporosis in children: diagnosis and management. Eur J Endocrinol. 2015;173:185-197. Epub 2015 Jun 3

15

Golden NH, Abrams SA; Committee on Nutrition. Optimizing bone health in children and adolescents. Pediatrics. 2014;134:e1229-1243.

16

Steelman J, Zeitler P. Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr. 2003;142:417-423.

17

Ooi HL, Briody J, Biggin A, Cowell CT, Munns CF. Intravenous zoledronic Acid given every 6 months in childhood osteoporosis. Horm Res Paediatr. 2013;80:179-184. Epub 2013 Sep 18

18

Lim A, Simm PJ, James S, Lee SL, Zacharin M. Outcomes of Zoledronic Acid Use in Paediatric Conditions. Horm Res Paediatr. 2021;93:442-452. Epub 2021 Jan 28

19

George S, Weber DR, Kaplan P, Hummel K, Monk HM, Levine MA. Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience. J Clin Endocrinol Metab. 2015;100:4163-4171. Epub 2015 Aug 26

20

Winzenberg T, Jones G. Vitamin D and bone health in childhood and adolescence. Calcif Tissue Int. 2013;92:140-150. Epub 2012 Jun 19

21

Galindo-Zavala R, Bou-Torrent R, Magallares-López B, Mir-Perelló C, Palmou-Fontana N, Sevilla-Pérez B, Medrano-San Ildefonso M, González-Fernández MI, Román-Pascual A, Alcañiz-Rodríguez P, Nieto-Gonzalez JC, López-Corbeto M, Graña-Gil J. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr Rheumatol Online J. 2020;18:20.

22

Simm PJ, Biggin A, Zacharin MR, Rodda CP, Tham E, Siafarikas A, Jefferies C, Hofman PL, Jensen DE, Woodhead H, Brown J, Wheeler BJ, Brookes D, Lafferty A, Munns CF; APEG Bone Mineral Working Group. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health. 2018;54:223-233.

23

Celin MR, Simon JC, Krzak JJ, Fial AV, Kruger KM, Smith PA, Harris GF. Do Bisphosphonates Alleviate Pain in Children? A Systematic Review. Curr Osteoporos Rep. 2020;18:486-504. Erratum in: Curr Osteoporos Rep. 2022;20:226.

24

Al-Agha AE, Shaikhain TA, Ashour AA. Safety & Efficacy of Cyclic Zoledronic Acid Therapy on Pediatric Secondary Osteoporosis. Glob J Health Sci. 2016;8:48648.

25

Sees JP, Sitoula P, Dabney K, Holmes L Jr, Rogers KJ, Kecskemethy HH, Bachrach S, Miller F. Pamidronate Treatment to Prevent Reoccurring Fractures in Children With Cerebral Palsy. J Pediatr Orthop. 2016;36:193-197.

26

Allington N, Vivegnis D, Gerard P. Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. Acta Orthop Belg. 2005;71:91-97.

27

Naithani R, Seth T, Tandon N, Chandra J, Choudhry VP, Pati H, Saxena R. Zoledronic Acid for Treatment of Low Bone Mineral Density in Patients with Beta Thalassemia Major. Indian J Hematol Blood Transfus. 2018;34:648-652. Epub 2018 Mar 27

28

Lee JM, Kim JE, Bae SH, Hah JO. Efficacy of pamidronate in children with low bone mineral density during and after chemotherapy for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Res. 2013;48:99-106. Epub 2013 Jun 25

29

Kim SD, Cho BS. Pamidronate therapy for preventing steroid-induced osteoporosis in children with nephropathy. Nephron Clin Pract. 2006;102:81-87. Epub 2005 Nov 10

30

Ward LM, Choudhury A, Alos N, Cabral DA, Rodd C, Sbrocchi AM, Taback S, Padidela R, Shaw NJ, Hosszu E, Kostik M, Alexeeva E, Thandrayen K, Shenouda N, Jaremko JL, Sunkara G, Sayyed S, Aftring RP, Munns CF. Zoledronic Acid vs Placebo in Pediatric Glucocorticoid-induced Osteoporosis: A Randomized, Double-blind, Phase 3 Trial. J Clin Endocrinol Metab. 2021;106:5222-5235.

31

Ooi HL, Briody J, McQuade M, Munns CF. Zoledronic acid improves bone mineral density in pediatric spinal cord injury. J Bone Miner Res. 2012;27:1536-1540.

32

Munns CF, Rajab MH, Hong J, Briody J, Högler W, McQuade M, Little DG, Cowell CT. Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone. 2007;41:366-370. Epub 2007 May 13

33

Nasomyont N, Hornung LN, Gordon CM, Wasserman H. Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review. Bone. 2019;121:60-67. Epub 2019 Jan 4

34

Högler W, Yap F, Little D, Ambler G, McQuade M, Cowell CT. Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr. 2004;145:701-704.